Screener examples › Short Sellers & Contrarian
Priced for perfection
Extreme valuations without cash support.
“Companies with price-to-sales above 20, negative free cash flow and heavy insider selling”
Run this screen live and refine it in plain English (free, no sign-up).
US operating companies with P/S above 20, negative free cash flow and heavy net insider selling over 90 days.
Filters: Price/Sales > 20; TTM free cash flow < 0; Insider sells (90d) ≥ 5; Net insider value (90d) < 0
Top matches on data as of October 26, 2026
| Symbol | Company | P/S | FCF (TTM) | Insider Sells 90D | Insider Buys 90D | Net Insider Value 90D | Market Cap (USD) | Revenue TTM (USD) | Rev Growth YoY |
|---|---|---|---|---|---|---|---|---|---|
| AUR | Aurora Innovation, Inc. | 1,925 | $-751.0M | 10 | 0 | $-655.8M | $9.6B | $5.0M | 4.0% |
| CBRS | Cerebras Systems Inc. | 24.04 | $-596.4M | 203 | 0 | $-387.7M | $16.4B | $680.7M | 90.8% |
| NBIS | Nebius Group N.V. | 31.67 | $-5.9B | 66 | 8 | $-157.0M | $42.9B | $1.4B | 4.6% |
| RLAY | Relay Therapeutics, Inc. | 355 | $-212.2M | 10 | 0 | $-120.4M | $3.7B | $10.4M | 23.9% |
| TWST | Twist Bioscience Corporation | 20.99 | $-93.1M | 76 | 0 | $-119.7M | $9.1B | $431.8M | 19.2% |
| SLN | Silence Therapeutics plc | 381 | $-56.4M | 11 | 0 | $-116.9M | $311.4M | $818255.37 | -97.6% |
| MRNA | Moderna, Inc. | 35.34 | $-1.2B | 12 | 0 | $-62.6M | $78.7B | $2.2B | -27.2% |
| ROIV | Roivant Sciences Ltd. | 3,450 | $-814.0M | 19 | 0 | $-59.9M | $26.0B | $7.5M | -67.6% |
| SPCX | Space Exploration Technologies Corp. | 56.31 | $-38.2B | 5 | 0 | $-52.5M | $1754.3B | $31.2B | |
| OKLO | Oklo Inc. | 3,778 | $-275.8M | 52 | 0 | $-31.0M | $4.6B | $1.2M | |
| RYTM | Rhythm Pharmaceuticals, Inc. | 25.58 | $-150.5M | 20 | 0 | $-28.8M | $6.1B | $239.9M | 53.5% |
| RKLB | Rocket Lab USA, Inc. | 44.06 | $-371.1M | 25 | 0 | $-27.0M | $33.9B | $769.1M | 52.5% |
| DNTH | Dianthus Therapeutics, Inc. | 2,334 | $-155.7M | 30 | 0 | $-26.1M | $4.4B | $1.9M | -60.8% |
| AEHR | Aehr Test Systems | 34.09 | $-5.4M | 18 | 0 | $-17.3M | $1.7B | $50.9M | -13.7% |
| SYRE | Spyre Therapeutics, Inc. | 86.99 | $-208.9M | 42 | 0 | $-16.9M | $7.9B | $90.5M | |
| HTFL | Heartflow, Inc. Common Stock | 23.22 | $-59.2M | 18 | 0 | $-15.5M | $4.9B | $212.1M | 42.8% |
| GRAL | GRAIL Inc. | 36.5 | $-295.3M | 21 | 0 | $-14.8M | $6.0B | $165.3M | 23.1% |
| CYTK | Cytokinetics, Incorporated | 113 | $-580.7M | 16 | 0 | $-12.9M | $8.0B | $71.0M | -17.2% |
| AEVA | Aeva Technologies, Inc. | 29.67 | $-116.7M | 14 | 0 | $-11.8M | $640.9M | $21.6M | 56.2% |
| JOBY | Joby Aviation, Inc. | 39.11 | $-744.3M | 20 | 0 | $-10.7M | $4.5B | $116.3M | 1185.7% |
| TRDA | Entrada Therapeutics, Inc. | 42.8 | $-134.4M | 33 | 0 | $-10.3M | $200.6M | $4.7M | -94.1% |
| AVR | Anteris Technologies Global Corp. | 251 | $-88.1M | 10 | 5 | $-9.8M | $562.6M | $2.2M | -9.6% |
| MAZE | Maze Therapeutics, Inc. | 91.65 | $-106.8M | 32 | 0 | $-6.1M | $1.8B | $20.0M | 7.0% |
| RAPP | Rapport Therapeutics, Inc. Common Stock | 60.12 | $-97.1M | 20 | 7 | $-5.3M | $1.2B | $20.0M | |
| CRSP | CRISPR Therapeutics AG | 353 | $-373.8M | 7 | 0 | $-4.9M | $4.7B | $13.4M | -64.2% |
25 matches. Research data, not investment advice.